Firebrick Pharma Ltd has released a press release.
Nasodine COVID-19 Trial Concludes Recruitment
Filed with ASX ·
6ix hasn’t read this filing yet.
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- Firebrick Pharmas Phase 3 Trial of Nasodine Resumes
- FRE files EU Paediatric Investigation Plan for Nasodine
- Appendix 4D & Half Yearly Report and Accounts
- December 2022 Quarterly Activity Report & Appendix 4C
- Nasodine Composition Patent Accepted in Australia
Later from Firebrick Pharma
- March 2023 Quarterly Activity Report & Appendix 4C
- Firebrick Raises $1 million via Placement
- Nasodine Phase 3 Clinical Trial Surpasses 80% Recruitment
- June 2023 Quarterly Activity Report & Appendix 4C
- Firebrick Covid-19 Trial Achieves Primary Endpoint
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma